Singapore markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3137+0.0737 (+5.96%)
As of 01:35PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 314.34M
Enterprise value 194.38M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.76
Price/book (mrq)12.90
Enterprise value/revenue 10.59
Enterprise value/EBITDA -1.71

Trading information

Stock price history

Beta (5Y monthly) 2.30
52-week change 337.62%
S&P500 52-week change 323.95%
52-week high 32.0500
52-week low 30.4200
50-day moving average 31.0677
200-day moving average 30.9565

Share statistics

Avg vol (3-month) 31.6M
Avg vol (10-day) 31.91M
Shares outstanding 5255.56M
Implied shares outstanding 6226.17M
Float 81.02B
% held by insiders 10.39%
% held by institutions 164.67%
Shares short (28 Jun 2024) 45.64M
Short ratio (28 Jun 2024) 42.49
Short % of float (28 Jun 2024) 43.31%
Short % of shares outstanding (28 Jun 2024) 42.21%
Shares short (prior month 31 May 2024) 44.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 330 Mar 2018
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-867.58%

Management effectiveness

Return on assets (ttm)-44.57%
Return on equity (ttm)-301.91%

Income statement

Revenue (ttm)18.36M
Revenue per share (ttm)0.08
Quarterly revenue growth (yoy)-88.10%
Gross profit (ttm)N/A
EBITDA -183.91M
Net income avi to common (ttm)-163.41M
Diluted EPS (ttm)-0.7300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)143.65M
Total cash per share (mrq)0.09
Total debt (mrq)23.69M
Total debt/equity (mrq)97.20%
Current ratio (mrq)2.81
Book value per share (mrq)0.09

Cash flow statement

Operating cash flow (ttm)-135.55M
Levered free cash flow (ttm)-95.08M